Lakefront Biotherapeutics N.V. (GLPG) is a Biotechnology company in the Healthcare sector, listed on Euronext Amsterdam. This page provides the complete earnings calendar, dividend schedule, and financial data for Lakefront Biotherapeutics N.V. in 2026.
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Lakefront Biotherapeutics N.V. (GLPG) last reported earnings on August 10, 2026.
Lakefront Biotherapeutics N.V. (GLPG) is listed on Euronext Amsterdam.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.